China has developed a new rabies vaccine, which has shown promise in preclinical trials. According to Xinhua, this is a live attenuated vaccine that was created and tested by scientists at the Wuhan Institute of Virology at the Chinese Academy of Sciences and at Huazhong Agricultural University.
The vaccine is based on the chimeric VEEV-RABV-G virus – in the Venezuelan equine encephalitis virus (VEEV), all structural proteins were replaced with rabies virus glycoprotein (RABV-G) as a single structural protein.
The study showed that the VEEV-RABV-G virus can self-propagate to high titers in cell culture without the help of any other structural proteins.
The safety and efficacy of the vaccine has so far been proven by the example of rodents: the vaccine provoked an immune response at a relatively low dose, provoking significantly weaker inflammation and fewer side effects compared to traditional rabies vaccines.